Application for approval for adults unable to consent to their own treatment to participate in a clinical trial (SPICE III Trial)

The case before the court involved an application by the Public and Consumer Health Research Unit of the University of Technology, Sydney, for approval for adults unable to consent to participate in the SPICE III Trial. The trial aimed to compare standard care sedation strategies in intensive care units, including the use of dexmedetomidine, a medication not currently approved by the Therapeutic Goods Administration (TGA) for use beyond a specified duration. The court was required to determine whether the trial constituted a clinical trial under the Clinical Trial Notification Scheme of the Therapeutic Goods Act 1989, and if so, whether adults unable to consent could participate. Additionally, the court needed to decide whether the ‘delayed consent’ provisions of the Guardianship Act were applicable.

The central legal issues revolved around the definition of a clinical trial and the applicability of the Guardianship Act to the situation. The court had to consider whether the trial's randomisation of treatment and the use of a medication beyond its TGA authority qualified it as a clinical trial. Furthermore, the court needed to determine if the Guardianship Act's delayed consent provisions applied, which would allow for the participation of adults unable to consent in the trial.

The court found that the SPICE III Trial did indeed constitute a clinical trial under the Therapeutic Goods Act, given the randomisation of treatment and the use of dexmedetomidine beyond its TGA-approved use. The court held that the ‘delayed consent’ provisions of the Guardianship Act were not applicable to this scenario. Consequently, the court approved the trial, granting the Public and Consumer Health Research Unit the authority to proceed with the SPICE III Trial. The court also determined that the function of giving or withholding consent for adults unable to consent would be exercised by the Tribunal.

The final orders of the court approved the SPICE III Trial as a clinical trial, allowing adults unable to consent to participate. The court assigned the responsibility of giving or withholding consent for these individuals to the Tribunal, ensuring that the trial could proceed under the appropriate legal framework.